Survival Following Relapse in Children with Acute Myeloid Leukemia: A Report from AML-BFM and COG.

TitleSurvival Following Relapse in Children with Acute Myeloid Leukemia: A Report from AML-BFM and COG.
Publication TypeJournal Article
Year of Publication2021
AuthorsRasche M, Zimmermann M, Steidel E, Alonzo T, Aplenc R, Bourquin J-P, Boztug H, Cooper T, Gamis AS, Gerbing RB, Janotova I, Klusmann J-H, Lehrnbecher T, Mühlegger N, Neuhoff NV, Niktoreh N, Sramkova L, Stary J, Waack K, Walter C, Creutzig U, Dworzak M, Kaspers G, Kolb EAnders, Reinhardt D
JournalCancers (Basel)
Volume13
Issue10
Date Published2021 May 12
ISSN2072-6694
Abstract

Post-relapse therapy remains critical for survival in children with acute myeloid leukemia (AML). We evaluated survival, response and prognostic variables following relapse in independent cooperative group studies conducted by COG and the population-based AML-BFM study group. BFM included 197 patients who relapsed after closure of the last I-BFM relapse trial until 2017, while COG included 852 patients who relapsed on the last Phase 3 trials (AAML0531, AAML1031). Overall survival at 5 years (OS) was 42 ± 4% (BFM) and 35 ± 2% (COG). Initial high-risk features (BFM 32 ± 6%, COG 26 ± 4%) and short time to relapse (BFM 29 ± 4%, COG 25 ± 2%) predicted diminished survival. In the BFM dataset, there was no difference in OS for patients who had a complete remission with full hematopoietic recovery (CR) following post-relapse re-induction compared to those with partial neutrophil and platelet recovery (CRp and CRi) only (52 ± 7% vs. 63 ± 10%, = 0.39). Among 90 patients alive at last follow-up, 87 had received a post-relapse hematopoietic stem cell transplant (HSCT). OS for patients with post-relapse HSCT was 54 ± 4%. In conclusion, initial high-risk features and early relapse remain prognostic. Response assessment with full hematopoietic recovery following initial relapse therapy does not predict survival. These data indicate the need for post-relapse risk stratification in future studies of relapse therapies.

DOI10.3390/cancers13102336
Alternate JournalCancers (Basel)
PubMed ID34066095
Grant List50-2728, 110244, 70112486 / / Deutsche Krebshilfe /
NCTN Operations Center Grant U10CA180886; NCTN Statistics & Data Center Grant U10CA180899; Chair's Grant U10CA098543 Statistics & Data Center Grant U10CA098413 (2003-2014) / CA / NCI NIH HHS / United States
grant agreement 714226 / / H2020 European Research Council /